Testosterone therapy and cardiovascular events among meta-analysis of placebo-controlled randomized trials

BMC Medicine 11, 108 DOI: 10.1186/1741-7015-11-108

Citation Report

#	Article	IF	CITATIONS
1	Testosterone therapy and cardiovascular events. Nature Reviews Endocrinology, 2013, 9, 438-438.	9.6	3
2	Androgen activity and markers of inflammation among men in NHANES III. American Journal of Human Biology, 2013, 25, 622-628.	1.6	17
3	Beneficial and Adverse Effects of Testosterone on the Cardiovascular System in Men. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4300-4310.	3.6	86
4	Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men. New England Journal of Medicine, 2013, 369, 2455-2457.	27.0	61
5	Testosterone Therapy in Older Men with Late-Onset Hypogonadism: A Counter-Rationale. Endocrine Practice, 2013, 19, 853-863.	2.1	17
6	The importance of testosterone clinical trials. Nature Reviews Endocrinology, 2013, 9, 438-438.	9.6	1
7	Androgen activity, ischaemic heart disease and risk factors among men in <scp>NHANES III</scp> . European Journal of Clinical Investigation, 2013, 43, 1273-1281.	3.4	16
8	Plasma Levels of Nitrate and Risk of Prostate Cancer: A Prospective Study—Letter. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1637-1637.	2.5	Ο
9	Risks and Benefits of Late Onset Hypogonadism Treatment: An Expert Opinion. World Journal of Men?s Health, 2013, 31, 103.	3.3	84
10	Global trends in testosterone prescribing, 2000–2011: expanding the spectrum of prescription drug misuse. Medical Journal of Australia, 2013, 199, 548-551.	1.7	199
11	A Validated Age-Related Normative Model for Male Total Testosterone Shows Increasing Variance but No Decline after Age 40 Years. PLoS ONE, 2014, 9, e109346.	2.5	101
12	Author's reply to Hackett. BMJ, The, 2014, 349, g7245-g7245.	6.0	0
13	Testosterone Supplementation Improves Carbohydrate and Lipid Metabolism in Some Older Men with Abdominal Obesity. Journal of Gerontology & Geriatric Research, 2014, 03, 1000159.	0.1	9
14	A critical analysis of testosterone supplementation therapy and cardiovascular risk in elderly men. Canadian Urological Association Journal, 2014, 8, 356.	0.6	5
15	The erectile dysfunction as a cardiovascular risk factor. Italian Journal of Medicine, 2014, 8, 210.	0.3	1
16	The Implications of Low Testosterone on Mortality in Men. Current Sexual Health Reports, 2014, 6, 235-243.	0.8	4
17	Cardiovascular risks and elevation of serum DHT vary by route of testosterone administration: a systematic review and meta-analysis. BMC Medicine, 2014, 12, 211.	5.5	103
18	Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opinion on Drug Safety, 2014, 13, 1327-1351.	2.4	260

TATION REDO

#	Article	IF	CITATIONS
19	Genetically predicted testosterone and cardiovascular risk factors in men: a Mendelian randomization analysis in the Guangzhou Biobank Cohort Study. International Journal of Epidemiology, 2014, 43, 140-148.	1.9	48
20	An update on male hypogonadism therapy. Expert Opinion on Pharmacotherapy, 2014, 15, 1247-1264.	1.8	41
21	Testosterone Treatment Is a Potent Tumor Promoter for the Rat Prostate. Endocrinology, 2014, 155, 4629-4633.	2.8	34
22	Need for standardising adverse event reporting in testosterone trials. Evidence-Based Medicine, 2014, 19, 32-33.	0.6	6
23	Testosterone Deficiency, Cardiac Health, and Older Men. International Journal of Endocrinology, 2014, 2014, 1-10.	1.5	14
24	Adverse effects of testosterone replacement therapy: an update on the evidence and controversy. Therapeutic Advances in Drug Safety, 2014, 5, 190-200.	2.4	64
25	Testosterone and cardiovascular disease. Lancet Diabetes and Endocrinology,the, 2014, 2, 612-613.	11.4	4
26	Testosterone and cardiovascular disease–Author's reply. Lancet Diabetes and Endocrinology,the, 2014, 2, 613.	11.4	0
27	Testosterone and cardiovascular disease. Lancet Diabetes and Endocrinology,the, 2014, 2, 612.	11.4	3
28	Testosterone Replacement Therapy: Who to Evaluate, What to Use, How to Follow, and Who is at Risk?. Hospital Practice (1995), 2014, 42, 69-82.	1.0	5
29	Estradiol concentrations in young healthy US <i>versus</i> Chinese men. American Journal of Human Biology, 2014, 26, 565-569.	1.6	4
30	Testosterone 2% Gel Can Normalize Testosterone Concentrations in Men with Low Testosterone Regardless of Body Mass Index. Journal of Sexual Medicine, 2014, 11, 857-864.	0.6	6
31	Testosterone and mortality. Clinical Endocrinology, 2014, 81, 477-487.	2.4	56
32	Why do statins reduce cardiovascular disease more than other lipid modulating therapies?. European Journal of Clinical Investigation, 2014, 44, 1135-1140.	3.4	16
33	Characteristics of Compensated Hypogonadism in Patients with Sexual Dysfunction. Journal of Sexual Medicine, 2014, 11, 1823-1834.	0.6	39
34	Height, its components, and coagulability among older Chinese : The Guangzhou biobank cohort study. American Journal of Human Biology, 2014, 26, 603-608.	1.6	1
35	Promotion of "Low T―and the Role of Testosterone Clinical Trials—Reply. JAMA Internal Medicine, 2014, 174, 306.	5.1	1
36	Risk of Myocardial Infarction in Older Men Receiving Testosterone Therapy. Annals of Pharmacotherapy, 2014, 48, 1138-1144.	1.9	177

#		IE	CITATIONS
#	Testosterone aging and survival Current Oninion in Endocrinology Diabetes and Obesity 2014-21	IF	CHATIONS
38	209-216.	2.3	43
39	Testosterone, thrombophilia, thrombosis. Blood Coagulation and Fibrinolysis, 2014, 25, 683-687.	1.0	21
40	Testosterone and cardiovascular disease. Cardiovascular Endocrinology, 2014, 3, 117-122.	0.8	0
41	Testosterone and cardiovascular disease. Current Opinion in Endocrinology, Diabetes and Obesity, 2014, 21, 202-208.	2.3	11
42	The Association of Free Testosterone Levels in Men and Lifestyle Factors and Chronic Disease Status. Journal of Primary Care and Community Health, 2014, 5, 173-179.	2.1	5
43	Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Asian Journal of Andrology, 2014, 16, 146.	1.6	89
44	Promotion of "Low T―and the Role of Testosterone Clinical Trials. JAMA Internal Medicine, 2014, 174, 305.	5.1	0
45	Testosterone therapy, thrombosis, thrombophilia, cardiovascular events. Metabolism: Clinical and Experimental, 2014, 63, 989-994.	3.4	60
46	In Older Men an Optimal Plasma Testosterone Is Associated With Reduced All-Cause Mortality and Higher Dihydrotestosterone With Reduced Ischemic Heart Disease Mortality, While Estradiol Levels Do Not Predict Mortality. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E9-E18.	3.6	155
47	Testosterone Lab Testing and Initiation in the United Kingdom and the United States, 2000 to 2011. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 835-842.	3.6	168
48	Mortality Associated to Late-Onset Hypogonadism: Reasons Not to Treat With Testosterone?. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1161-1163.	3.6	6
49	A Critical Analysis of the Role of Testosterone in Erectile Function: From Pathophysiology to Treatment—A Systematic Review. European Urology, 2014, 65, 99-112.	1.9	243
50	Low testosterone syndrome protects subjects with high cardiovascular risk burden from major adverse cardiovascular events. Andrology, 2014, 2, 741-747.	3.5	44
52	Testosterone levels and heart failure in obese and non-obese men. International Journal of Cardiology, 2014, 176, 1163-1166.	1.7	6
53	Cardiovascular disease in transsexual persons treated with cross-sex hormones: reversal of the traditional sex difference in cardiovascular disease pattern. European Journal of Endocrinology, 2014, 170, 809-819.	3.7	108
54	Commentary: Who Is a Candidate for Testosterone Therapy? A Synthesis of International Expert Opinions. Journal of Sexual Medicine, 2014, 11, 1636-1645.	0.6	34
55	Testosterone and glucose metabolism in men: current concepts and controversies. Journal of Endocrinology, 2014, 220, R37-R55.	2.6	84
56	Treatment strategies for diabetic patients suffering from erectile dysfunction: an update. Expert Opinion on Pharmacotherapy, 2014, 15, 1827-1836.	1.8	24

#	Article	IF	CITATIONS
57	Hormones and Cardiovascular Disease in Older Men. Journal of the American Medical Directors Association, 2014, 15, 326-333.	2.5	13
58	Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opinion on Pharmacotherapy, 2014, 15, 1903-1926.	1.8	66
59	Low testosterone elevates interleukin family cytokines in a rodent model: a possible mechanism for the potentiation of vascular disease in androgen-deficient males. Journal of Surgical Research, 2014, 190, 319-327.	1.6	38
60	Sexual selection as a driver of population health. Social Science and Medicine, 2014, 108, 243-245.	3.8	2
61	Outcomes of testosterone therapy in men with testosterone deficiency (TD): Part II. Steroids, 2014, 88, 117-126.	1.8	24
62	Increased heart attacks in men using testosterone: the UK importantly lags far behind the US in prescribing testosterone. BMJ, The, 2014, 348, g1789-g1789.	6.0	11
64	Comparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen. Sexual Medicine, 2015, 3, 165-173.	1.6	48
65	Basic Science Evidence for the Link Between Erectile Dysfunction and Cardiometabolic Dysfunction. Journal of Sexual Medicine, 2015, 12, 2233-2255.	0.6	43
66	Sarcopenia and frailty: new challenges for clinical practice. Clinical Medicine, 2015, 15, s88-s91.	1.9	52
67	Endothelial dysfunction, insulin resistance and inflammation in congenital hypogonadism, and the effect of testosterone replacement. Endocrine Journal, 2015, 62, 605-613.	1.6	8
68	American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of Testosterone and Cardiovascular Risk. Endocrine Practice, 2015, 21, 1066-1073.	2.1	62
69	Testosterone Replacement and Cardiovascular Safety: No Straight and Narrow!. Clinical Medicine Insights: Cardiology, 2015, 9, CMC.S23395.	1.8	2
70	Cardiometabolic effects of testosterone in older men. Cardiovascular Endocrinology, 2015, 4, 108-113.	0.8	1
71	Ascertainment of Testosterone Prescribing Practices in the VA. Medical Care, 2015, 53, 746-752.	2.4	46
72	Defining the best candidates for testosterone replacement?. Cardiovascular Endocrinology, 2015, 4, 77-82.	0.8	0
73	Testosterone supplementation in men. Current Opinion in Obstetrics and Gynecology, 2015, 27, 258-264.	2.0	4
74	Irrational Exuberance in Testosterone Prescribing. Medical Care, 2015, 53, 743-745.	2.4	20
75	Prevalence, Pathophysiology, and Management of Androgen Deficiency in Men with Metabolic Syndrome, Type 2 Diabetes Mellitus, or Both. Pharmacotherapy, 2015, 35, 780-792.	2.6	34

#	Article	IF	Citations
76	Testosterone replacement and cardiovascular disease risk. Cardiovascular Endocrinology, 2015, 4, 100-107.	0.8	2
77	Testosterone replacement therapy. Cardiovascular Endocrinology, 2015, 4, 90-94.	0.8	0
78	Update on the Treatment of Erectile Dysfunction. , 2015, , .		3
79	Testosterone Replacement Therapy and Cardiovascular Risk: A Review. World Journal of Men?s Health, 2015, 33, 130.	3.3	38
80	Alternatives to testosterone replacement: testosterone restoration. Asian Journal of Andrology, 2015, 17, 201.	1.6	16
81	Klinefelter Syndrome and medical treatment: hypogonadism and beyond. Hormones, 2015, 14, 531-48.	1.9	23
82	Traumatic andropause after combat injury. BMJ Case Reports, 2015, 2015, bcr2014207924.	0.5	4
83	Testosterone and cardiovascular disease risk. Current Opinion in Endocrinology, Diabetes and Obesity, 2015, 22, 193-202.	2.3	35
84	Testosterone replacement attenuates mitochondrial damage in a rat model of myocardial infarction. Journal of Endocrinology, 2015, 225, 101-111.	2.6	33
85	Leydig cell aging and hypogonadism. Experimental Gerontology, 2015, 68, 87-91.	2.8	93
86	Genetically predicted testosterone and electrocardiographic QT interval duration in Chinese: a Mendelian randomization analysis in the Guangzhou Biobank Cohort Study. International Journal of Epidemiology, 2015, 44, 613-620.	1.9	12
87	Hypogonadism and Testosterone Therapy. American Journal of Men's Health, 2015, 9, 340-344.	1.6	2
88	Osteoporosis and Low Bone Mineral Density in Men with Testosterone Deficiency Syndrome. Sexual Medicine Reviews, 2015, 3, 298-315.	2.9	10
89	Testosterone therapy and prostate cancer—safety concerns are well founded. Nature Reviews Urology, 2015, 12, 48-54.	3.8	21
90	Testosterone Therapy and Cardiovascular Risk: Advances and Controversies. Mayo Clinic Proceedings, 2015, 90, 224-251.	3.0	165
91	Current topics in testosterone replacement of hypogonadal men. Best Practice and Research in Clinical Endocrinology and Metabolism, 2015, 29, 77-90.	4.7	47
92	Effect of androgen replacement therapy on atherosclerotic risk markers in youngâ€ŧoâ€middleâ€aged men with idiopathic hypogonadotropic hypogonadism. Clinical Endocrinology, 2015, 82, 422-428.	2.4	16
93	Effects of testosterone on lean mass gain in elderly men: systematic review with meta-analysis of controlled and randomized studies. Age, 2015, 37, 9742.	3.0	50

#	Article	IF	CITATIONS
94	Pulmonary and cardiovascular toxicity in long-term testicular cancer survivors. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 399-406.	1.6	46
95	The Impact of Testosterone Therapy in Men on Cardiovascular Risk. Mayo Clinic Proceedings, 2015, 90, 163-165.	3.0	2
96	The Role of Testosterone Therapy in Cardiovascular Mortality: Culprit or Innocent Bystander?. Current Atherosclerosis Reports, 2015, 17, 490.	4.8	4
97	Integrated Therapies for Osteoporosis and Sarcopenia: From Signaling Pathways to Clinical Trials. Calcified Tissue International, 2015, 96, 243-255.	3.1	32
98	Testosterone Therapy and Risk of Myocardial Infarction: A Pharmacoepidemiologic Study. Pharmacotherapy, 2015, 35, 72-78.	2.6	53
99	Testosterone and Cardiovascular Health: Safety of Treatment of Hypogonadism. Sexual Medicine Reviews, 2015, 3, 56-62.	2.9	11
100	Differential risks in men and women for first and recurrent venous thrombosis: the role of genes and environment: comment. Journal of Thrombosis and Haemostasis, 2015, 13, 884-886.	3.8	17
101	Transdermal delivery of testosterone. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 92, 42-48.	4.3	34
102	Cross-sex hormone therapy for gender dysphoria. Journal of Endocrinological Investigation, 2015, 38, 269-282.	3.3	21
103	Promotion of "Low T―and citation bias in testosterone studies. International Journal of Cardiology, 2015, 184, 510-511.	1.7	6
104	Testosterone is associated with the cardiovascular autonomic response to a stressor in healthy men. Clinical and Experimental Hypertension, 2015, 37, 184-191.	1.3	10
105	Testosterone deficiency and cardiovascular mortality. Asian Journal of Andrology, 2015, 17, 26.	1.6	19
106	Luteinizing hormone as a key player in the cognitive decline of Alzheimer's disease. Hormones and Behavior, 2015, 76, 48-56.	2.1	26
107	Does falling testosterone with age among men underlie the increase in ischaemic heart disease. Journal of Epidemiology and Community Health, 2015, 69, 393-396.	3.7	4
108	Testosterone threshold – does one size fit all?. Aging Male, 2015, 18, 1-4.	1.9	9
109	Abnormalities of Reproductive Function in Male Obesity Before and After Bariatric Surgery—A Comprehensive Review. Obesity Surgery, 2015, 25, 1281-1292.	2.1	18
110	Testosterone supplementation and cardiovascular risk. Trends in Cardiovascular Medicine, 2015, 25, 258-260.	4.9	4
111	Testosterone therapy and cardiovascular risk. Trends in Cardiovascular Medicine, 2015, 25, 250-257.	4.9	16

#	Article	IF	CITATIONS
112	Testosterone Replacement Therapy and the Internet: An Assessment of Providers' Health-related Web Site Information Content. Urology, 2015, 85, 814-818.	1.0	12
113	Testosterone in men with hypogonadism and high cardiovascular risk, Pros. Endocrine, 2015, 50, 320-325.	2.3	2
114	Debate: Testosterone Therapy Reduces Cardiovascular Risk in Men with Diabetes. Against the Motion. Current Cardiovascular Risk Reports, 2015, 9, 1.	2.0	0
115	Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology. Journal of Endocrinological Investigation, 2015, 38, 103-112.	3.3	103
116	5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia. Journal of Endocrinological Investigation, 2015, 38, 799-805.	3.3	6
117	Complications of injectable testosterone undecanoate in routine clinical practice. European Journal of Endocrinology, 2015, 172, 511-517.	3.7	33
118	Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older men. American Journal of Physiology - Endocrinology and Metabolism, 2015, 308, E1035-E1042.	3.5	47
119	Testosterone replacement therapy among HIV-infected men in the CFAR Network of Integrated Clinical Systems. Aids, 2015, 29, 77-81.	2.2	11
120	Androgen levels in women with various forms of ovarian dysfunction: associations with cardiometabolic features. Human Reproduction, 2015, 30, 2376-2386.	0.9	58
121	Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. European Heart Journal, 2015, 36, 2706-2715.	2.2	249
122	Low testosterone is associated with poor health status in men with human immunodeficiency virus infection: a retrospective study. Andrology, 2015, 3, 298-308.	3.5	41
123	Adolescent testosterone, muscle mass and glucose metabolism: evidence from the â€~Children of 1997' birth cohort in Hong Kong. Diabetic Medicine, 2015, 32, 505-512.	2.3	24
124	Pharmacologic androgen deprivation and cardiovascular disease risk factors: a systematic review. European Journal of Clinical Investigation, 2015, 45, 475-484.	3.4	9
125	The practical management of testosterone deficiency in men. Nature Reviews Urology, 2015, 12, 641-650.	3.8	53
126	Use of statins is associated with lower serum total and non-sex hormone-binding globulin-bound testosterone levels in male participants of the Rotterdam Study. European Journal of Endocrinology, 2015, 173, 155-165.	3.7	24
127	Mediation analysis of the relationship between sex, cardiovascular risk factors and mortality from coronary heart disease: Findings from the population-based VHM&PP cohort. Atherosclerosis, 2015, 243, 86-92.	0.8	15
128	Serum Testosterone (T) Level Variability in T Gel-Treated Older Hypogonadal Men: Treatment Monitoring Implications. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3280-3287.	3.6	38
129	An update on testosterone, HDL and cardiovascular risk in men. Clinical Lipidology, 2015, 10, 251-258.	0.4	24

#	Article	IF	Citations
130	The complex and multifactorial relationship between testosterone deficiency (TD), obesity and vascular disease. Reviews in Endocrine and Metabolic Disorders, 2015, 16, 249-268.	5.7	42
131	The International Society for Sexual Medicine's Process of Care for the Assessment and Management of Testosterone Deficiency in Adult Men. Journal of Sexual Medicine, 2015, 12, 1660-1686.	0.6	119
132	The effect of ezetimibe-statin combination on steroid hormone production in men with coronary artery disease and low cholesterol levels. Pharmacological Reports, 2015, 67, 305-309.	3.3	6
133	Sexual Dysfunction in Chronic Kidney Disease. , 2015, , 350-363.		1
134	Transgender populations and HIV: unique risks, challenges and opportunities. Journal of Virus Eradication, 2016, 2, 87-93.	0.5	29
135	Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study. Vascular Health and Risk Management, 2016, 12, 251.	2.3	37
136	ACQUIRED HYPOGONADOTROPIC HYPOGONADISM (AHH) IN THALASSAEMIA MAJOR PATIENTS: AN UNDERDIAGNOSED CONDITION?. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, 2016001.	1.3	28
137	Endocrinology and Aging. , 2016, , 1234-1251.		5
138	Testicular Disorders. , 2016, , 694-784.		12
139	Off label therapies for testosterone replacement. Translational Andrology and Urology, 2016, 5, 844-849.	1.4	6
140	Testosterone replacement therapy and the heart: friend, foe or bystander?. Translational Andrology and Urology, 2016, 5, 898-908.	1.4	11
141	Endocrine Society of Australia position statement on male hypogonadism (part 2): treatment and therapeutic considerations. Medical Journal of Australia, 2016, 205, 228-231.	1.7	45
142	Testosterone therapy in men with testosterone deficiency: Are we beyond the point of no return?. Investigative and Clinical Urology, 2016, 57, 384.	2.0	24
143	Testosterone treatment and risk of venous thromboembolism: population based case-control study. BMJ, The, 2016, 355, i5968.	6.0	125
144	Effect of testosterone on insulin sensitivity, oxidative metabolism and body composition in aging men with type 2 diabetes on metformin monotherapy. Diabetes, Obesity and Metabolism, 2016, 18, 980-989.	4.4	50
145	The Cardiovascular Trial of the Testosterone Trials. Coronary Artery Disease, 2016, 27, 95-103.	0.7	12
146	Testosterone therapy, association with age, initiation and mode of therapy with cardiovascular events: a systematic review. Clinical Endocrinology, 2016, 85, 436-443.	2.4	77
147	Mendelian randomization estimates of alanine aminotransferase with cardiovascular disease: Guangzhou Biobank Cohort study. Human Molecular Genetics, 2017, 26, ddw396.	2.9	24

#	Article	IF	CITATIONS
148	Effects of Testosterone Replacement on Electrocardiographic Parameters in Men: Findings from Two Randomized Trials. Journal of Clinical Endocrinology and Metabolism, 2016, 102, jc.2016-3669.	3.6	14
149	Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1318-1343.	3.6	48
150	Effect of testosterone treatment on cardiac biomarkers in a randomized controlled trial of men with type 2 diabetes. Clinical Endocrinology, 2016, 84, 55-62.	2.4	13
151	Survival and cardiovascular events in men treated with testosterone replacement therapy: an intention-to-treat observational cohort study. Lancet Diabetes and Endocrinology,the, 2016, 4, 498-506.	11.4	126
152	Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. European Journal of Epidemiology, 2016, 31, 337-350.	5.7	1,761
153	Testosterone Replacement Therapy and the Cardiovascular System. Current Atherosclerosis Reports, 2016, 18, 19.	4.8	1
154	An update on the role of testosterone replacement therapy in the management of hypogonadism. Therapeutic Advances in Urology, 2016, 8, 147-160.	2.0	21
155	Four Thrombotic Events Over 5 Years, Two Pulmonary Emboli and Two Deep Venous Thrombosis, When Testosterone-HCG Therapy Was Continued Despite Concurrent Anticoagulation in a 55-Year-Old Man With Lupus Anticoagulant. Journal of Investigative Medicine High Impact Case Reports, 2016, 4, 232470961666183.	0.6	5
156	Is Sex Good for Your Health? A National Study on Partnered Sexuality and Cardiovascular Risk among Older Men and Women. Journal of Health and Social Behavior, 2016, 57, 276-296.	4.8	115
157	Testosterone therapy in men with testosterone deficiency: are the benefits and cardiovascular risks real or imagined?. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2016, 311, R566-R573.	1.8	19
158	Effect of l-arginine, asymmetric dimethylarginine, and symmetric dimethylarginine on ischemic heart disease risk: A Mendelian randomization study. American Heart Journal, 2016, 182, 54-61.	2.7	17
159	Adjunct Management of Male Hypogonadism. Current Sexual Health Reports, 2016, 8, 231-239.	0.8	1
160	Sarcopenia and frailty: new challenges for clinical practice. Clinical Medicine, 2016, 16, 455-458.	1.9	63
161	Association between exogenous testosterone and cardiovascular events: an overview of systematic reviews. Lancet Diabetes and Endocrinology,the, 2016, 4, 943-956.	11.4	92
162	Testosterone prescribing in the population-a short social epidemiological analysis in Sweden. Pharmacoepidemiology and Drug Safety, 2016, 25, 11-15.	1.9	4
163	Variations in costs and use of provincially-funded testosterone replacement therapy across Canada: a population-based study. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 803-807.	1.4	Ο
164	Temporal Changes in Androgens and Estrogens Are Associated With All-Cause and Cause-Specific Mortality in Older Men. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2201-2210.	3.6	41
165	Endogenous androgen exposures and ischemic heart disease, a separate sample Mendelian randomization study. International Journal of Cardiology, 2016, 222, 940-945.	1.7	14

#	Article	IF	CITATIONS
166	Adult-Onset Hypogonadism. Mayo Clinic Proceedings, 2016, 91, 908-926.	3.0	74
167	Low Testosterone in Men with Cardiovascular Disease or Risk Factors: To Treat or Not To Treat?. Current Treatment Options in Cardiovascular Medicine, 2016, 18, 75.	0.9	8
168	Sex Hormone Influenced Differences in Skeletal Muscle Responses to Aging and Exercise. , 2016, , 167-180.		0
169	Could androgens be relevant to partly explain why men have lower life expectancy than women?. Journal of Epidemiology and Community Health, 2016, 70, 324-328.	3.7	25
170	Predictive value of serum testosterone for type 2 diabetes risk assessment in men. BMC Endocrine Disorders, 2016, 16, 26.	2.2	31
171	Comparisons of chromosome Y-substituted mouse strains reveal that the male-specific chromosome modulates the effects of androgens on cardiac functions. Biology of Sex Differences, 2016, 7, 61.	4.1	5
172	Association Between Testosterone Replacement Therapy and the Incidence ofÂDVT andÂPulmonaryÂEmbolism. Chest, 2016, 150, 563-571.	0.8	56
173	Fundamental Concepts Regarding Testosterone Deficiency and Treatment. Mayo Clinic Proceedings, 2016, 91, 881-896.	3.0	88
174	Sex Steroids, Sex Hormone-Binding Globulin and Cardiovascular Health in Men and Postmenopausal Women: The Rotterdam Study. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2844-2852.	3.6	37
175	Testosterone supplementation and body composition: results from a meta-analysis of observational studies. Journal of Endocrinological Investigation, 2016, 39, 967-981.	3.3	147
176	Author's Response to the Letter: Does the optimal BMI really vary by age and sex?, by Xu <i>etÂal</i> International Journal of Epidemiology, 2016, 45, 286-287.	1.9	1
177	Sex Hormones and Ischemic Stroke: A Prospective Cohort Study and Meta-Analyses. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 69-78.	3.6	71
178	Androgens. Frontiers of Hormone Research, 2016, 47, 82-100.	1.0	2
179	Effects of testosterone replacement on metabolic and inflammatory markers in men with opioidâ€induced androgen deficiency. Clinical Endocrinology, 2016, 85, 232-238.	2.4	19
180	Adaptation to acute coronary syndrome-induced stress with lowering of testosterone: a possible survival factor. European Journal of Endocrinology, 2016, 174, 481-489.	3.7	9
181	Does the optimal BMI really vary by age and sex?. International Journal of Epidemiology, 2016, 45, 285-286.	1.9	6
182	Cigarette smoking and testosterone in men and women: A systematic review and meta-analysis of observational studies. Preventive Medicine, 2016, 85, 1-10.	3.4	63
183	Left ventricular dysfunction and subclinical atherosclerosis in children with classic congenital adrenal hyperplasia: a single-center study from Upper Egypt. European Journal of Pediatrics, 2016, 175, 415-415.	2.7	6

#	Article	IF	CITATIONS
184	Left ventricular dysfunction and subclinical atherosclerosis in children with classic congenital adrenal hyperplasia: a single-center study from upper Egypt. European Journal of Pediatrics, 2016, 175, 405-412.	2.7	14
185	Testosterone: a hormone preventing cardiovascular disease or a therapy increasing cardiovascular events?. European Heart Journal, 2016, 37, 3569-3575.	2.2	30
186	Effects of Testosterone Treatment in Older Men. New England Journal of Medicine, 2016, 374, 611-624.	27.0	675
187	Sarcopenic Obesity. , 2016, , 665-678.		0
188	Testosterone and Cardiovascular Disease. Journal of the American College of Cardiology, 2016, 67, 545-557.	2.8	279
189	Circulating Sex Steroids and Vascular Calcification in Community-Dwelling Men: The Framingham Heart Study. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2160-2167.	3.6	20
190	Factors that may be influencing the rise in prescription testosterone replacement therapy in adult men: a qualitative study. Aging Male, 2016, 19, 90-95.	1.9	11
191	Male Hormonal Contraception: Where Are We Now?. Current Obstetrics and Gynecology Reports, 2016, 5, 38-47.	0.8	49
192	Management of Hypogonadism in Cardiovascular Patients. Urologic Clinics of North America, 2016, 43, 247-260.	1.8	6
193	2-Chloro-4-[[(1 <i>R</i> ,2 <i>R</i>)-2-hydroxy-2-methyl-cyclopentyl]amino]-3-methyl-benzonitrile: A Transdermal Selective Androgen Receptor Modulator (SARM) for Muscle Atrophy. Journal of Medicinal Chemistry, 2016, 59, 750-755.	6.4	33
194	Prospective longitudinal study of testosterone and incident depression in older men: The Health In Men Study. Psychoneuroendocrinology, 2016, 64, 57-65.	2.7	58
195	Testosterone deficiency in the aging male. Therapeutic Advances in Urology, 2016, 8, 47-60.	2.0	71
196	Testosterone Replacement Therapy and Mortality in Older Men. Drug Safety, 2016, 39, 117-130.	3.2	23
197	Androgen Physiology, Pharmacology, and Abuse. , 2016, , 2368-2393.e16.		11
198	Male hormonal contraception: hope and promise. Lancet Diabetes and Endocrinology,the, 2017, 5, 214-223.	11.4	19
199	Testosterone Replacement Therapy: The Emperor's New Clothes. Rejuvenation Research, 2017, 20, 9-14.	1.8	17
200	Standards for Clinical Trials in Male and Female Sexual Dysfunction: III.ÂUnique Aspects of Clinical Trials in Male Sexual Dysfunction. Journal of Sexual Medicine, 2017, 14, 3-18.	0.6	12
201	Blood donation and testosterone replacement therapy. Transfusion, 2017, 57, 578-581.	1.6	5

		TION REPORT	
#	Article	IF	CITATIONS
202	Industry sponsorship and research outcome. The Cochrane Library, 2017, 2017, MR000033.	2.8	772
203	Long-Term Testosterone Therapy Improves Cardiometabolic Function and Reduces Risk of Cardiovascular Disease in Men with Hypogonadism. Journal of Cardiovascular Pharmacology and Therapeutics, 2017, 22, 414-433.	2.0	109
204	Testosterone Treatment and Cardiovascular and Venous Thromboembolism Risk: What is â€~New'?. Journal of Investigative Medicine, 2017, 65, 964-973.	1.6	46
205	Practice Patterns in the Diagnosis and Management of Hypogonadism: A Survey of Sexual Medicine Society of North America Members. Urology, 2017, 106, 87-95.	1.0	3
206	Androgen Replacement Therapy in Hypogonadal Men. , 2017, , 367-397.		0
207	MR spectroscopy of hepatic fat and adiponectin and leptin levels during testosterone therapy in type 2 diabetes: a randomized, double-blinded, placebo-controlled trial. European Journal of Endocrinology, 2017, 177, 157-168.	3.7	22
208	Anabolic steroids for treating pressure ulcers. The Cochrane Library, 2017, 6, CD011375.	2.8	4
209	State-of-the-Art: a Review of Cardiovascular Effects of Testosterone Replacement Therapy in Adult Males. Current Cardiology Reports, 2017, 19, 35.	2.9	16
210	Testosterone and Cardiovascular Effects. , 2017, , 299-318.		0
211	Testosterone Misuse and Abuse. , 2017, , 375-402.		0
212	UK policy statements on testosterone deficiency. International Journal of Clinical Practice, 2017, 71, e12901.	1.7	8
213	Cardiovascular and Metabolic Consequences of Testosterone Supplements in Young and Old Male Spontaneously Hypertensive Rats: Implications for Testosterone Supplements in Men. Journal of the American Heart Association, 2017, 6, .	3.7	19
214	A review of sarcopenia: Enhancing awareness of an increasingly prevalent disease. Bone, 2017, 105, 276-286.	2.9	217
215	Pharmacoepidemiology of testosterone: Curbing off-label prescribing. Pharmacoepidemiology and Drug Safety, 2017, 26, 1248-1255.	1.9	8
216	Testosterone therapy preserves muscle strength and power in aging men with type 2 diabetes—a randomized controlled trial. Andrology, 2017, 5, 946-953.	3.5	16
217	Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy. Annals of Internal Medicine, 2017, 167, 256.	3.9	151
218	Normalization of Testosterone Levels After Testosterone Replacement Therapy Is Not Associated With Reduced Myocardial Infarction in Smokers. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2017, 1, 57-66.	2.4	10
219	Low Plasma Testosterone is Associated with Elevated Cardiovascular Disease Biomarkers. Journal of Sexual Medicine, 2017, 14, 1095-1103.	0.6	27

#	Article	IF	CITATIONS
220	Cardiovascular Health, Erectile Dysfunction, and Testosterone Replacement: Controversies and Correlations. Urology, 2017, 110, 1-8.	1.0	10
221	Androgens and cardiovascular disease in women and men. Maturitas, 2017, 104, 54-72.	2.4	23
222	Approaches to male hypogonadism in primary care. Nurse Practitioner, 2017, 42, 32-37.	0.3	8
223	Association of Testosterone Replacement Therapy and the Incidence of a Composite of Postoperative In-hospital Mortality and Cardiovascular Events in Men Undergoing Noncardiac Surgery. Anesthesiology, 2017, 127, 457-465.	2.5	16
224	Testosterone and sexual function. Current Opinion in Urology, 2017, 27, 516-518.	1.8	2
226	Negative Impact of Testosterone Deficiency and 5î±-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men. Advances in Experimental Medicine and Biology, 2017, 1043, 473-526.	1.6	32
227	British Society for Sexual Medicine Guidelines on Adult Testosterone Deficiency, with Statements for UK Practice. Journal of Sexual Medicine, 2017, 14, 1504-1523.	0.6	94
228	Testosterone and Cardiovascular Diseases: Causes or Consequences: The Lesson from the Last 5 Years. Current Sexual Health Reports, 2017, 9, 277-289.	0.8	0
229	Testosterone Therapy and Risk of Acute Myocardial Infarction in Hypogonadal Men: An Administrative Health Care Claims Study. Journal of Sexual Medicine, 2017, 14, 1307-1317.	0.6	11
230	Testosterone vs. aromatase inhibitor in older men with low testosterone: effects on cardiometabolic parameters. Andrology, 2017, 5, 31-40.	3.5	15
231	Aging and sex hormones in males. Virulence, 2017, 8, 545-570.	4.4	102
232	Testosterone Deficiency and Testosterone Treatment in Older Men. Gerontology, 2017, 63, 144-156.	2.8	100
233	Cardiovascular Risks of Exogenous Testosterone Use Among Men: A Systematic Review and Meta-Analysis. American Journal of Medicine, 2017, 130, 293-305.	1.5	96
234	The appropriateness and persistence of testosterone replacement therapy in Ontario. Pharmacoepidemiology and Drug Safety, 2017, 26, 119-126.	1.9	7
235	Perioperative Testosterone Supplementation Increases Lean Mass in Healthy Men Undergoing Anterior Cruciate Ligament Reconstruction: A Randomized Controlled Trial. Orthopaedic Journal of Sports Medicine, 2017, 5, 232596711772279.	1.7	15
236	Testosterone Replacement Therapy: Long-Term Safety and Efficacy. World Journal of Men?s Health, 2017, 35, 65.	3.3	48
237	From Sarcopenia to Frailty: The Pathophysiological Basis and Potential Target Molecules of Intervention. , 2017, , .		4
238	Testosterone, Sex Hormone-Binding Globulin and Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Annals of Hepatology, 2017, 16, 382-394.	1.5	89

#	Article	IF	CITATIONS
239	Pharmacological management of late-onset hypogonadism. Expert Review of Clinical Pharmacology, 2018, 11, 439-458.	3.1	34
240	Cardiovascular benefits and risks of testosterone replacement therapy in older men with low testosterone. Hospital Practice (1995), 2018, 46, 47-55.	1.0	7
241	Testosterone replacement therapy: For whom, when and how?. Metabolism: Clinical and Experimental, 2018, 86, 69-78.	3.4	69
242	The state of testosterone therapy since the FDA's 2015 labelling changes: Indications and cardiovascular risk. Clinical Endocrinology, 2018, 89, 3-10.	2.4	13
243	The complex association between metabolic syndrome and male hypogonadism. Metabolism: Clinical and Experimental, 2018, 86, 61-68.	3.4	41
244	Injection testosterone and adverse cardiovascular events: AÂcaseâ€crossover analysis. Clinical Endocrinology, 2018, 88, 719-727.	2.4	8
245	The safety of available treatments of male hypogonadism in organic and functional hypogonadism. Expert Opinion on Drug Safety, 2018, 17, 277-292.	2.4	33
246	The Intersection of Medicine and Urology. Medical Clinics of North America, 2018, 102, 399-415.	2.5	5
247	Hypogonadism. Medical Clinics of North America, 2018, 102, 361-372.	2.5	6
248	Longitudinal change instead of baseline testosterone predicts depressive symptoms. Psychoneuroendocrinology, 2018, 89, 7-12.	2.7	22
249	Testosterone and androstanediol glucuronide among men in NHANES III. BMC Public Health, 2018, 18, 339.	2.9	2
250	Leydig cells: formation, function, and regulationâ€. Biology of Reproduction, 2018, 99, 101-111.	2.7	370
251	Thromboembolism Peaking 3 Months after Starting Testosterone Therapy: Testosterone–Thrombophilia Interactions. Journal of Investigative Medicine, 2018, 66, 733-738.	1.6	6
252	Benefits and Health Implications of Testosterone Therapy in Men With Testosterone Deficiency. Sexual Medicine Reviews, 2018, 6, 86-105.	2.9	34
253	Body composition changes with testosterone replacement therapy following spinal cord injury and aging: A mini review. Journal of Spinal Cord Medicine, 2018, 41, 624-636.	1.4	24
254	Testosterone replacement therapy for physician assistants and nurse practitioners. Translational Andrology and Urology, 2018, 7, S63-S71.	1.4	2
255	Testosterone Administration Alters Hepatic Blood Flow Across Age: Systematic Review of Animal Experimental Studies. Journal of Morphological Sciences, 2018, 35, 096-101.	0.2	1
256	Testosterone supplementation in men with sexual dysfunction. The Cochrane Library, 0, , .	2.8	2

		CITATION RE	PORT	
#	Article		IF	CITATIONS
257	Mechanisms of Sex Disparities in Cardiovascular Function and Remodeling. , 2018, 9, 3	375-411.		12
258	Testosterone therapy and venous thromboembolism: A systematic review and meta-an Thrombosis Research, 2018, 172, 94-103.	alysis.	1.7	52
259	Androgens and the Regulation of Adiposity and Body Fat Distribution in Humans. , 201	.8, 8, 1253-1290.		53
260	Effects of testosterone and progressive resistance exercise on vascular function in olde Journal of Applied Physiology, 2018, 125, 1693-1701.	er men.	2.5	16
261	Sex Hormones and Alzheimerâ \in ^M s Disease. , 2018, , .			2
262	Sex differences in lipid and lipoprotein metabolism. Molecular Metabolism, 2018, 15, 4	-5-55.	6.5	286
263	Testosterone and Cardiovascular Risk: Meta-Analysis of Interventional Studies. Journal Medicine, 2018, 15, 820-838.	of Sexual	0.6	91
264	Testosterone, frailty and physical function in older men. Expert Review of Endocrinolog Metabolism, 2018, 13, 159-165.	y and	2.4	15
265	Testosterone, myocardial function, and mortality. Heart Failure Reviews, 2018, 23, 773	3-788.	3.9	25
266	Low Serum Testosterone is Present in Nearly Half of Men Undergoing Artificial Urinary Placement. Urology, 2018, 118, 208-212.	Sphincter	1.0	9
267	Role of androgens in energy metabolism affecting on body composition, metabolic syn diabetes, cardiovascular disease, and longevity: lessons from a meta-analysis and roder Bioscience, Biotechnology and Biochemistry, 2018, 82, 1667-1682.	idrome, type 2 it studies.	1.3	24
268	Leydig Cells: Fetal to Aged Testes. , 2018, , 39-41.			1
269	Hormone Replacement Therapy in Men. , 2018, , 735-740.			0
270	Gonadopenia And Aging In Men. Endocrine Practice, 2018, 24, 375-385.		2.1	4
271	To T or not to T: Differences in Testosterone Use and Discontinuation by HIV Serostatu who Have Sex with Men. HIV Medicine, 2018, 19, 634-644.	ıs among Men	2.2	6
272	Treatment Approaches to Sexual Dysfunction in Late Life. Current Treatment Options i 2018, 5, 255-274.	n Psychiatry,	1.9	0
273	Short-term combined treatment with exenatide and metformin is superior to glimepiric metformin in improvement of serum testosterone levels in type 2 diabetic patients wit Andrologia, 2018, 50, e13039.	le combined h obesity.	2.1	16
274	Male Hormonal Contraception. , 2018, , 741-750.			1

#	Article	IF	CITATIONS
275	Emerging Evidences in the Long Standing Controversy Regarding Testosterone Replacement Therapy and Cardiovascular Events. World Journal of Men?s Health, 2018, 36, 92.	3.3	7
276	Endogenous Testosterone Levels and Cardiovascular Risk: Meta-Analysis of Observational Studies. Journal of Sexual Medicine, 2018, 15, 1260-1271.	0.6	115
277	Cardiovascular impact of testosterone therapy for hypogonadism. Expert Review of Cardiovascular Therapy, 2018, 16, 617-625.	1.5	11
278	Industry sponsorship and research outcome: systematic review with meta-analysis. Intensive Care Medicine, 2018, 44, 1603-1612.	8.2	97
279	Leydig Cell Development and Aging in the Brown Norway Rat. , 2018, , 853-862.		2
280	An analysis of online content related to testosterone supplementation. Aging Male, 2019, 22, 141-149.	1.9	6
281	Analysis of cardiovascular risk factors associated with serum testosterone levels according to the US 2011–2012 National Health and Nutrition Examination Survey. Aging Male, 2019, 22, 121-128.	1.9	13
282	Testosterone Management in Aging Males: Surveying Clinical Practices of Urologists and Endocrinologists in Israel. Sexual Medicine, 2019, 7, 409-417.	1.6	4
283	Late-Onset Hypogonadism as Primary Testicular Failure. Frontiers in Endocrinology, 2019, 10, 372.	3.5	5
284	Monitoring testosterone replacement therapy with transdermal gel: when and how?. Journal of Endocrinological Investigation, 2019, 42, 1491-1496.	3.3	5
285	Primary human testicular PDGFRα+ cells are multipotent and can be differentiated into cells with Leydig cell characteristics in vitro. Human Reproduction, 2019, 34, 1621-1631.	0.9	19
286	Impaired systolic and diastolic left ventricular function in children and adolescents with congenital adrenal hyperplasia receiving corticosteroid therapy. Cardiology in the Young, 2019, 29, 319-324.	0.8	2
287	Type 2 Diabetes and Testosterone Therapy. World Journal of Men?s Health, 2019, 37, 31.	3.3	27
288	Aging and the Male Reproductive System. Endocrine Reviews, 2019, 40, 906-972.	20.1	85
289	Paediatric and adult-onset male hypogonadism. Nature Reviews Disease Primers, 2019, 5, 38.	30.5	153
290	Obesity's role in secondary male hypogonadism: a review of pathophysiology and management issues. SN Comprehensive Clinical Medicine, 2019, 1, 408-418.	0.6	4
291	Testosterone replacement therapy and cardiovascular risk. Nature Reviews Cardiology, 2019, 16, 555-574.	13.7	136
292	Testosterone deficiency reduces cardiac hypertrophy in a rat model of severe volume overload. Physiological Reports, 2019, 7, e14088.	1.7	10

#	Article	IF	CITATIONS
293	Testosterone Deficiency: A Review and Comparison of Current Guidelines. Journal of Sexual Medicine, 2019, 16, 812-820.	0.6	31
294	An update on heart disease risk associated with testosterone boosting medications. Expert Opinion on Drug Safety, 2019, 18, 321-332.	2.4	14
295	Gender, hormone therapy, and HIV: what should cardiologists know?. Netherlands Heart Journal, 2019, 27, 233-236.	0.8	1
296	Testosterone moderates the effects of social support on cardiovascular disease risk factors among older US men. American Journal of Human Biology, 2019, 31, e23248.	1.6	2
297	Cardiovascular Risks Associated with Gender and Aging. Journal of Cardiovascular Development and Disease, 2019, 6, 19.	1.6	404
298	Cardiovascular Outcomes and All-cause Mortality Following Measurement of Endogenous Testosterone Levels. American Journal of Cardiology, 2019, 123, 1757-1764.	1.6	11
299	Late-onset Hypogonadism and Testosterone Therapy – A Summary of Guidelines from the American Urological Association and the European Association of Urology. European Urology Focus, 2019, 5, 539-544.	3.1	27
300	Metabolic Effects of Testosterone Therapy in Men with Type 2 Diabetes and Metabolic Syndrome. Sexual Medicine Reviews, 2019, 7, 476-490.	2.9	24
301	Aging Muscle and Sarcopenia. , 2019, , 120-120.		4
302	Androgens and depression: a review and update. Current Opinion in Endocrinology, Diabetes and Obesity, 2019, 26, 175-179.	2.3	13
303	Testosterone Replacement Therapy. , 2019, , 79-93.		3
304	Testosterone Therapy, Thrombophilia, Venous Thromboembolism, and Thrombotic Events. Journal of Clinical Medicine, 2019, 8, 11.	2.4	27
305	Testosterone, testosterone therapy and prostate cancer. Aging Male, 2019, 22, 219-227.	1.9	52
306	Sex-Specific Associations of Androgen Receptor CAG Trinucleotide Repeat Length and of Raloxifene Treatment with Testosterone Levels and Perceived Stress in Schizophrenia. Molecular Neuropsychiatry, 2019, 5, 28-41.	2.9	3
307	A systematic review of randomized controlled trials investigating the efficacy and safety of testosterone therapy for female sexual dysfunction in postmenopausal women. Clinical Endocrinology, 2019, 90, 391-414.	2.4	28
308	Acute effects of the translocator protein drug ligand FGIN-1-27 on serum testosterone and luteinizing hormone levels in male Sprague-Dawley ratsâ€. Biology of Reproduction, 2019, 100, 824-832.	2.7	7
309	Interactive effects of testosterone and the androgen receptor CAG repeat length polymorphism on cardiovascularâ€renal events and mortality in men with diabetes. Diabetes/Metabolism Research and Reviews, 2019, 35, e3081.	4.0	8
310	Testosterone deficiency in men with Type 2 diabetes: pathophysiology and treatment. Diabetic Medicine, 2020, 37, 174-186.	2.3	46

#	ARTICLE Sexual Dysfunction in Chronic Kidney Disease. , 2020, , 593-611.	IF	CITATIONS 3
312	Effect of treatment with testosterone on endothelial function in hypogonadal men: a systematic review and meta-analysis. International Journal of Impotence Research, 2020, 32, 379-386.	1.8	21
313	Lateâ€onset hypogonadism: a concept comes of age. Andrology, 2020, 8, 1506-1511.	3.5	67
314	Male Sexual and Reproductive Health—Does the Urologist Have a Role in Addressing Gender Inequality in Life Expectancy?. European Urology Focus, 2020, 6, 791-800.	3.1	11
315	Association of Testosterone Replacement Therapy and the Incidence of a Composite of Postoperative In-Hospital Mortality and Cardiovascular Events in Men Undergoing Cardiac Surgery. Anesthesia and Analgesia, 2020, 130, 890-898.	2.2	8
316	Cardiovascular risk with androgen deprivation therapy. International Journal of Clinical Practice, 2020, 74, e13449.	1.7	3
317	Suppression of myofilament cross-bridge kinetic in the heart of orchidectomized rats. Life Sciences, 2020, 261, 118342.	4.3	2
318	Effectiveness of testosterone therapy in hypogonadal patients and its controversial adverse impact on the cardiovascular system. Critical Reviews in Toxicology, 2020, 50, 491-512.	3.9	2
319	Retinoic acid receptor antagonists for male contraception: current statusâ€. Biology of Reproduction, 2020, 103, 390-399.	2.7	21
320	Efficacy and Safety of Testosterone Treatment in Men: An Evidence Report for a Clinical Practice Guideline by the American College of Physicians. Annals of Internal Medicine, 2020, 172, 105.	3.9	41
321	Testosterone deficiency syndrome: Diagnosis and treatment. Actas Urológicas Españolas (English) Tj ETQq0 0	0 rgBT /O	verlock 10 Tf
322	Hypogonadism management and cardiovascular health. Postgraduate Medicine, 2020, 132, 35-41.	2.0	4
323	Reflections on the T Trials. Andrology, 2020, 8, 1512-1518.	3.5	8
324	In Experimental Dilated Cardiomyopathy Heart Failure and Survival Are Adversely Affected by a Lack of Sexual Interactions. International Journal of Molecular Sciences, 2020, 21, 5450.	4.1	4
325	A comparative analysis of human adult testicular cells expressing stem Leydig cell markers in the interstitium, vasculature, and peritubular layer. Andrology, 2020, 8, 1265-1276.	3.5	11
326	Exogenous Testosterone Abuse and Myocardial Infarction in a Young Bodybuilder. American Journal of Medicine, 2020, 133, e665-e666.	1.5	4
327	Sarcopenia: A Contemporary Health Problem among Older Adult Populations. Nutrients, 2020, 12, 1293.	4.1	195
328	Understanding Erectile Dysfunction in Hypertensive Patients: The Need for Good Patient Management. Vascular Health and Risk Management, 2020, Volume 16, 231-239.	2.3	10

#	Article	IF	CITATIONS
329	Testosterone therapy in hypogonadal patients and the associated risks of cardiovascular events. Biomedicine and Pharmacotherapy, 2020, 129, 110423.	5.6	3
330	The effects of testosterone on bone health in males with testosterone deficiency: a systematic review and meta-analysis. BMC Endocrine Disorders, 2020, 20, 33.	2.2	15
331	Critical evaluation of different available guidelines for lateâ€onset hypogonadism. Andrology, 2020, 8, 1628-1641.	3.5	34
332	BMI1 promotes steroidogenesis through maintaining redox homeostasis in mouse MLTC-1 and primary Leydig cells. Cell Cycle, 2020, 19, 1884-1898.	2.6	21
333	No evidence found for an association between trial characteristics and treatment effects in randomized trials of testosterone therapy in men: a meta-epidemiological study. Journal of Clinical Epidemiology, 2020, 122, 12-19.	5.0	5
334	Testosterone Therapy: What We Have Learned From Trials. Journal of Sexual Medicine, 2020, 17, 447-460.	0.6	50
335	Testosterone concentrations and risk of cardiovascular events in androgen-deficient men with atherosclerotic cardiovascular disease. American Heart Journal, 2020, 224, 65-76.	2.7	30
336	Role of Androgens in Cardiovascular Diseases in Men: A Comprehensive Review. , 0, , .		1
337	Testosterone Therapy and Cardiovascular Risk: A Critical Analysis of Studies Reporting Increased Risk. Journal of Sexual Medicine, 2021, 18, 83-98.	0.6	10
338	Metabolic disorders: Sex and gender evidence in dyslipidemia, diabetes, and obesity. , 2021, , 171-205.		0
339	Androgen Misuse and Abuse. Endocrine Reviews, 2021, 42, 457-501.	20.1	41
340	Leydig cell aging: Molecular mechanisms and treatments. Vitamins and Hormones, 2021, 115, 585-609.	1.7	12
341	Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. European Heart Journal, 2021, 42, 967-984.	2.2	136
342	Effects of Exogenous Androgens on Platelet Activity and Their Thrombogenic Potential in Supraphysiological Administration: A Literature Review. Journal of Clinical Medicine, 2021, 10, 147.	2.4	19
343	Cardiovascular risk and testosterone $\hat{a} \in$ from subclinical atherosclerosis to lipoprotein function to heart failure. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 257-274.	5.7	26
344	Serum free testosterone level in coronary artery disease in candidates for coronary artery bypass graft surgery: A cross-sectional study. International Journal of Reproductive BioMedicine, 2021, 19, 293-302.	0.9	1
345	Testosterone replacement therapy and the risk of venous thromboembolism: A systematic review and meta-analysis of randomized controlled trials. Thrombosis Research, 2021, 199, 123-131.	1.7	18
346	Mental Health of Men in Later Life. , 2021, , 251-262.		0

ARTICLE IF CITATIONS Persistent inflammation, immunosuppression and catabolism syndrome: mechanisms of sarcopenia and 348 0.2 0 ways of correction. Emergency Medicine, 2020, 16, 110-117. Diagnostyka i leczenie niedoboru testosteronu u mężczyzn na podstawie wytycznych europejskich i 349 0.1 amerykańskich towarzystw urologicznych. Postepy Higieny I Medycyny Doswiadcźalnej, 2021, 75, 217-228. Late-onset hypogonadism: Clinical evidence, biological aspects and evolutionary considerations. 350 10.9 7 Ageing Research Reviews, 2021, 67, 101301. Serum testosterone levels and testosterone supplementation in cirrhosis: A systematic review. Liver 351 3.9 International, 2021, 41, 2358-2370. The impact of rosuvastatin on hypothalamic–pituitary–testicular axis activity in metformin-treated and metformin-naÃ-ve men with low testosterone levels: a pilot study. Pharmacological Reports, 2021, 352 3.3 3 73, 1465-1472. A Novel Liver-Targeted Testosterone-Therapy for Sarcopenia in Androgen Deprived Men with Prostate Cancer. Journal of the Endocrine Society, 2021, 5, bvab116. 0.2 Age-Related Testosterone Deficiency Merits Treatment. Androgens: Clinical Research and Therapeutics, 354 0.5 1 2021, 2, 46-55. Anabolic-Androgenic Steroid Use in Sports, Health, and Society. Medicine and Science in Sports and 0.4 20 Exercise, 2021, 53, 1778-1794. How Would You Manage This Male Patient With Hypogonadism?. Annals of Internal Medicine, 2021, 174, 356 3.9 1 1133-1142. Association Between Testosterone Treatment and Risk of Incident Cardiovascular Events Among US Male Veterans With Low Testosterone Levels and Multiple Medical Comorbidities. Journal of the American Heart Association, 2021, 10, e020562. Energy Metabolism Focused Analysis of Sexual Dimorphism in Biological Aging and Hypothesized 358 3 3.4 Sex-specificity in Sirtuin Dependency. Mitochondrion, 2021, 60, 85-100. Hematologic Disorders and Stroke., 2022, , 592-603.e6. Genetically Predicted Sex Hormone Binding Globulin and Ischemic Heart Disease: A Sex-Specific 360 0.4 0 Mendelian Randomization Study. SSRN Electronic Journal, 0, , . Correlation of the severity of obstruction in coronary arteries with serum free testosterone level. 0.1 Journal of Indian College of Cardiology, 2021, 11, 116. 362 Sexuality in later life., 2021, , 151-164. 1 Use, Misuse, and Abuse of Androgens. Endocrinology, 2017, , 1251-1285. 0.1 Systematic Review of the Impact of Testosterone Replacement Therapy on Depression in Patients with 364 3.121 Late-onset Testosterone Deficiency. European Urology Focus, 2020, 6, 170-177. Testosterone therapy in hypogonadal men: a systematic review and network meta-analysis. BMJ Open, 2017, 7, e015284.

#	Article	IF	CITATIONS
366	Review of health risks of low testosterone and testosterone administration. World Journal of Clinical Cases, 2015, 3, 338.	0.8	22
367	Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men. PLoS ONE, 2014, 9, e85805.	2.5	600
368	Low Serum Testosterone Levels Are Associated with Elevated Urinary Mandelic Acid, and Strontium Levels in Adult Men According to the US 2011–2012 National Health and Nutrition Examination Survey. PLoS ONE, 2015, 10, e0127451.	2.5	8
369	Treatment of Men for "Low Testosterone†A Systematic Review. PLoS ONE, 2016, 11, e0162480.	2.5	72
370	The Rise and Fall of Estrogen Therapy: Is Testosterone for "Manopause―Next?. Texas Heart Institute Journal, 2017, 44, 338-340.	0.3	3
371	Cardiovascular benefits and risks of testosterone replacement therapy in hypogonadal men with type 2 diabetes mellitus and/or the metabolic syndrome: a systematic review. British Journal of Diabetes, 2018, 18, 141-146.	0.2	4
372	MANAGEMENT OF ENDOCRINE DISEASE: Rationale and current evidence for testosterone therapy in the management of obesity and its complications. European Journal of Endocrinology, 2020, 183, R167-R183.	3.7	16
373	Testosterone and the Heart. European Cardiology Review, 2019, 14, 103-110.	2.2	39
374	A Review of the Relationships Between Endogenous Sex Steroids and Incident Ischemic Stroke and Coronary Heart Disease Events. Current Cardiology Reviews, 2015, 11, 252-260.	1.5	26
375	Dehydroepiandrosterone Sulfate as a Risk Factor for Premature Myocardial Infarction: A Comparative Study. Korean Journal of Family Medicine, 2015, 36, 1.	1.2	5
376	Selective androgen receptor modulators for the treatment of late onset male hypogonadism. Asian Journal of Andrology, 2014, 16, 256.	1.6	16
377	Sex steroids and cardiovascular disease. Asian Journal of Andrology, 2014, 16, 239.	1.6	20
378	Controversies in testosterone replacement therapy: testosterone and cardiovascular disease. Asian Journal of Andrology, 2015, 17, 187.	1.6	26
379	Testosterone treatment and cardiovascular events in prescription database studies. Asian Journal of Andrology, 2018, 20, 138.	1.6	12
380	Trials of testosterone replacement reporting cardiovascular adverse events. Asian Journal of Andrology, 2018, 20, 131.	1.6	9
381	Metabolic syndrome and hypogonadism – two peas in a pod. Swiss Medical Weekly, 2016, 146, w14283.	1.6	16
382	Have the Testosterone Trials Demonstrated the Effectiveness of Testosterone Therapy in Older Men without Classical Hypogonadism?. Journal of the Royal College of Physicians of Edinburgh, The, 2016, 46, 168-171.	0.6	5
383	Testosterone and Cardiovascular Disease in Men. Journal of Steroids & Hormonal Science, 2013, 05, .	0.1	0

#	Article	IF	CITATIONS
385	Plasma Testosterone and Dihydrotestosterone as Markers of Heart Disease and Mortality in Older Men. , 2015, , 1-23.		0
387	Sarcopenic Obesity. , 2015, , 1-17.		0
388	What Are the Long-Term Toxicities to Be Controlled and Treated?. , 2015, , 115-125.		0
389	Anti-Obesity Effects of Androgens, Dehydroepiandrosterone (DHEA) and Testosterone. , 0, , .		0
390	Hypotestosteronaemia in the aging male: should we treat it?. Swiss Medical Weekly, 2015, 145, w14216.	1.6	6
391	Plasma Testosterone and Dihydrotestosterone as Markers of Heart Disease and Mortality in Older Men. , 2016, , 425-447.		0
392	Hypogonadism: The Relationship to Cardiometabolic Syndrome and the Controversy Behind Testosterone Replacement Therapy. , 2016, , 249-267.		0
393	Treatment of Hypogonadism. Endocrinology, 2017, , 945-978.	0.1	0
394	Use, Misuse, and Abuse of Androgens. Endocrinology, 2017, , 1-35.	0.1	0
395	Androgen Therapy for Hypogonadism in Men with Chronic Illnesses. , 2017, , 399-422.		2
396	Hypogonadism in Systemic Diseases. Endocrinology, 2017, , 829-879.	0.1	4
397	Hypogonadism in Systemic Diseases. Endocrinology, 2017, , 1-51.	0.1	2
398	Treatment of Hypogonadism. Endocrinology, 2017, , 1-34.	0.1	0
399	Testosteron bei Ĥeren MĤnern. Pharma-Kritik (discontinued), 2017, 38, .	0.0	0
400	Metaepidemiologie und Qualitäsicherung klinischer Evidenzproduktion. , 2018, , 49-64.		2
401	Testosterone replacement therapy: Dilemmas and challenges in China and Asia. Asian Journal of Andrology, 2018, 20, 149.	1.6	6
402	Do we have enough evidences that make you safe to treat a man with hypogonadism one year after a radical prostatectomy for prostate cancer? Opinion: Not Yet. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2018, 44, 8-13.	1.5	0
403	Sex Steroid Hormones and Osteosarcopenia. , 2019, , 173-190.		0

#	Article	IF	CITATIONS
404	Benefits and risks of testosterone therapy in older men. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 217-229.	3.9	1
405	An obese 48-year-old man with progressive fatigue and decreased libido. Cleveland Clinic Journal of Medicine, 2019, 86, 321-331.	1.3	0
406	Testosterone Level and Cause-Specific Mortality in Older Men without Metabolic Syndrome. Epidemiology and Health, 2020, 42, e2020036.	1.9	1
407	SÃndrome de déficit de testosterona: diagnóstico y tratamiento. Actas Urológicas Españolas, 2020, 44, 294-300.	0.7	2
408	Urologic Endocrinology. , 2020, , 151-158.		0
409	Dysfunction of Sexual and Accessory Sex Organs. , 2020, , 91-120.		0
410	Transgender populations and HIV: unique risks, challenges and opportunities. Journal of Virus Eradication, 2016, 2, 87-93.	0.5	17
411	Androgen action in prostate function and disease. American Journal of Clinical and Experimental Urology, 2018, 6, 62-77.	0.4	37
412	Genetically predicted sex hormone binding globulin and ischemic heart disease in men and women: a univariable and multivariable Mendelian randomization study. Scientific Reports, 2021, 11, 23172.	3.3	7
413	Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism. Clinical Endocrinology, 2022, 96, 200-219.	2.4	46
414	Effects of long-term testosterone treatment on cardiovascular outcomes in men with hypogonadism: Rationale and design of the TRAVERSE study. American Heart Journal, 2022, 245, 41-50.	2.7	42
415	Male hypogonadism with its systemic complications. Journal of Education, Health and Sport, 2020, 10, 183-199.	0.1	0
416	Risks of Testosterone Treatment. , 2022, , 1585-1590.		0
417	The Illusory Case for Treatment of an Invented Disease. Frontiers in Endocrinology, 2021, 12, 682620.	3.5	4
418	Role of sex hormones in modulating myocardial perfusion and coronary flow reserve. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2209-2218.	6.4	6
419	Trends in testosterone prescription amongst medical specialties: a 5-year CMS data analysis. International Journal of Impotence Research, 2023, 35, 1-5.	1.8	2
420	Testosterone replacement therapy and cardiovascular disease. International Journal of Impotence Research, 2022, 34, 685-690.	1.8	3
421	Testosterone Use in the Perioperative Setting. Current Sexual Health Reports, 0, , 1.	0.8	0

#	Article	IF	Citations
422	Genetically predicted sex hormone levels and health outcomes: phenome-wide Mendelian randomization investigation. International Journal of Epidemiology, 2022, 51, 1931-1942.	1.9	19
423	Testosterone Replacement Therapy in Hypogonadal Men. Endocrinology and Metabolism Clinics of North America, 2022, 51, 77-98.	3.2	10
424	Testosterone, Sex Hormone-Binding Globulin and Nonalcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. Annals of Hepatology, 2017, 16, 382-394.	1.5	66
426	The Role of Testosterone in the Elderly: What Do We Know?. International Journal of Molecular Sciences, 2022, 23, 3535.	4.1	41
427	Ageing male (part 2): Management of functional hypogonadism in older men, a patient-centric holistic approach. Best Practice and Research in Clinical Endocrinology and Metabolism, 2022, 36, 101626.	4.7	4
428	Obesity, Body Composition, and Sex Hormones: Implications for Cardiovascular Risk. , 2021, 12, 2949-2993.		11
429	Morbidity and mortality in men: Role of androgens. Best Practice and Research in Clinical Endocrinology and Metabolism, 2022, 36, 101662.	4.7	2
430	The Pre-Testosterone Therapy Checklist. Journal of Sexual Medicine, 2022, 19, 1214-1217.	0.6	2
431	Is Testosterone the "Fountain of Youth―for Aging Men?. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2022, 22, .	1.2	0
432	Evaluation of the Interaction of Sex Hormones and Cardiovascular Function and Health. Current Heart Failure Reports, 2022, 19, 200-212.	3.3	15
433	Association of sex hormone dynamics with 10-year survival in men with implanted cardiac resynchronization therapy devices. Journal of Arrhythmology, 2022, 29, 5-16.	0.2	1
434	Cardiovascular Morbidity and Mortality in Men – Findings from a Meta-analysis on the Time-related Measure of Risk of Exogenous Testosterone. Journal of Sexual Medicine, 2022, 19, 1243-1254.	0.6	5
435	Adverse cardiovascular events and mortality in men during testosterone treatment: an individual patient and aggregate data meta-analysis. The Lancet Healthy Longevity, 2022, 3, e381-e393.	4.6	39
436	The relationship between serum sex hormone and cardiac echocardiographic findings in healthy men. Scientific Reports, 2022, 12, .	3.3	2
437	Testosterone and congestive heart failure. Kardiologiya, 2022, 62, 61-67.	0.7	0
438	Glycemic Variability in Subjects with Diabetes and Hypogonadism during Testosterone Replacement Treatment: A Pilot Study. Journal of Clinical Medicine, 2022, 11, 5333.	2.4	2
439	Low Testosterone Level and Risk of Adverse Clinical Events among Male Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Cohort Studies. Journal of Healthcare Engineering, 2022, 2022, 1-10.	1.9	6
440	Low-Intensity Pulsed Ultrasound Alleviates Human Testicular Leydig Cell Senescence In Vitro. International Journal of Molecular Sciences, 2023, 24, 418.	4.1	4

#	Article	IF	CITATIONS
441	Sarcopenia: From clinical aspects to therapeutic possibilities. Srpski Medicinski Äasopis Lekarske Komore, 2022, 3, 436-445.	0.1	0
442	Testosterone Therapy in Oncologic Patients. Current Sexual Health Reports, 2023, 15, 18-25.	0.8	0
443	Testosterone therapy increases the anticoagulant potential in men with opioid-induced hypogonadism: a randomized, placebo-controlled study. Endocrine Connections, 2023, 12, .	1.9	2
444	Seneszenz und Altershypogonadismus. Springer Reference Medizin, 2023, , 1-23.	0.0	0
446	New Horizons: Testosterone or Exercise for Cardiometabolic Health in Older Men. Journal of Clinical Endocrinology and Metabolism, 2023, 108, 2141-2153.	3.6	1
447	Statin therapy and sex hormones. , 2023, , 551-571.		Ο
448	Safety and Efficacy of Testosterone Therapy on Musculoskeletal Health and Clinical Outcomes in Men: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Endocrine Practice, 2023, 29, 727-734.	2.1	1
449	Recent advances in endocrine organoids for therapeutic application. Advanced Drug Delivery Reviews, 2023, 199, 114959.	13.7	2
450	Breastfeeding and ApoB in late adolescence: a Hong Kong birth cohort study. European Journal of Pediatrics, 0, , .	2.7	0
451	Prospective Study of Associations Between Testosterone, Mortality, and Health Outcomes Among Adults Undergoing Hemodialysis. Kidney International Reports, 2023, , .	0.8	0
452	Cardiovascular Safety of Testosterone-Replacement Therapy. New England Journal of Medicine, 2023, 389, 107-117.	27.0	65
453	Hormones and Aging: An Endocrine Society Scientific Statement. Journal of Clinical Endocrinology and Metabolism, 2023, 108, 1835-1874.	3.6	13
454	Seneszenz und Altershypogonadismus. Springer Reference Medizin, 2023, , 339-361.	0.0	0
455	Higher testosterone and testosterone/estradiol ratio in men are associated with decreased Pheno-/GrimAge and DNA-methylation based PAI1. GeroScience, 2024, 46, 1053-1069.	4.6	0
456	Testosterone Replacement Therapy in Relation With Cardiovascular Disease in Cisgender Women and Transgender People. Journal of Clinical Endocrinology and Metabolism, 2023, 108, e1515-e1523.	3.6	1
457	Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database. Frontiers in Pharmacology, 0, 14, .	3.5	0
458	Testosterone and Cardiovascular Effects. , 2023, , 381-410.		0
459	Testosterone Misuse and Abuse. , 2023, , 481-508.		0

#	ARTICLE	IF	CITATIONS
460	Major cardiovascular disease risk in men with testosterone deficiency (hypogonadism): appraisal of short, medium and long-term testosterone therapy – a narrative review. Sexual Medicine Reviews, 2023, 11, 384-394.	0.0	2
461	Long-term Outcomes of Testosterone Treatment in Men: A T4DM Postrandomization Observational Follow-up Study. Journal of Clinical Endocrinology and Metabolism, 2023, 109, e25-e31.	3.6	2
462	Sarcopenic Obesity. , 2023, , 1-18.		0
463	A roadmap for sex- and gender-disaggregated health research. BMC Medicine, 2023, 21, .	5.5	3
464	Testosterone Replacement Therapy and Cardiovascular Disease: Balancing Safety and Risks in Hypogonadal Men. Current Cardiology Reports, 2023, 25, 1157-1163.	2.9	1
465	The association of testosterone with sarcopenia and frailty in chronic liver disease. European Journal of Clinical Investigation, 2024, 54, .	3.4	0
466	EMAS position statement: Testosterone replacement therapy in older men. Maturitas, 2023, 178, 107854.	2.4	0
467	Cardiovascular safety of testosterone replacement therapy. Urologie Pro Praxi, 2023, 24, 180-183.	0.1	0
468	Testosterone is positively associated with coronary artery calcium in a low cardiovascular disease risk population. Evolution, Medicine and Public Health, 0, , .	2.5	0
469	Testosterone replacement therapy is not associated with increased prostate cancer incidence, prostate cancer-specific, or cardiovascular disease-specific mortality in Finnish men. Acta Oncológica, 2023, 62, 1898-1904.	1.8	0
470	Testosterone replacement therapy and vascular thromboembolic events: a systematic review and meta-analysis. Asian Journal of Andrology, 2024, 26, 144-154.	1.6	0
471	Cardiometabolic Function in Women. , 2023, , 177-203.		0
472	Impact of testosterone levels and testosterone replacement ther-apy on men's health. Journal of Medical Science, 0, , e856.	0.7	0
473	Testosterone replacement in men with sexual dysfunction. The Cochrane Library, 2024, 2024, .	2.8	0
474	Assotiation of testosterone levels and oxidative stress activity with 10-year survival in men with cardiac resynchronization therapy. Journal of Arrhythmology, 2024, 31, 14-27.	0.2	0
475	Sarcopenic Obesity. , 2023, , 585-602.		0
476	Testosterone therapy and the risk of cardiovascular disease in older, hypogonadal men. Progress in Cardiovascular Diseases, 2024, , .	3.1	0